



European
Innovation
Council



Catalogue

BIO International Convention 2024



2- 6 June 2024
San Diego, USA

 #EUeic
 @EUeic
 eic.ec.europa.eu



Contents

What is the European Innovation Council?.....	4
What is the EIC International Trade Fairs & USA Soft-Landing Programme 3.0?	5
Meet the EIC awardees in attendance at BIO 2024	6
Find the EIC awardees at the European Pavilion	7
EIC awardee: Ability Pharma.....	8
EIC awardee: Acousort.....	9
EIC awardee: Beats Medical.....	10
EIC awardee: Genomtec.....	11
EIC awardee: Iris AI.....	12
EIC awardee: Kvantify.....	13
EIC awardee: Mcule.....	14
EIC awardee: MTM.....	15
EIC awardee: Peptomyc.....	16
EIC awardee: React4Life.....	17
EIC awardee: SDS Optic.....	18
EIC awardee: Stab Vida.....	19
EIC awardee: Vaultree.....	20
EIC awardee: VERIGRAFT.....	21
EIC awardee: Vitalera.....	22



1

What is the European Innovation Council?

The European Innovation Council (EIC) is Europe's flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations. The EIC has a budget of €10.1 billion to support innovation throughout the whole lifecycle, from early-stage research to proof of concept, technology transfer and the financing and scale up of startups and small companies.

The EIC functions under the following schemes:

- [EIC Pathfinder](#) supports research teams to research and/or develop emerging breakthrough technology.
- [EIC Transition](#) supports the maturation of a novel technology and development of a business case to bring it to market.
- [EIC Accelerator](#) supports funding and investments through the EIC Fund for individual startups and small companies to develop and scale up their breakthrough innovations.
- [EIC Fund](#) provides equity finance to startups and scaleups and it has a proactive approach to co-investing with other investors offering a pipeline of attractive opportunities.

EIC support goes however far beyond funding. It provides to the EIC top-notch innovators with access to a range of high quality tailor-made [Business Acceleration Services \(EIC BAS\)](#) helping thus the scaling up and commercialisation of the EIC innovations.

EIC Delegation to BIO 2024:



Robert Schröder
Head of Communication
European Innovation Council
Robert.Schroder@ec.europa.eu



Vassilis Tsanidis
Innovation Procurement Advisor
European Innovation Council
Vasileios.Tsanidis@ec.europa.eu



2 EIC International Trade Fairs (ITF) & USA Soft-landing Programme 3.0

Building on the experience of OTF 1.0 and 2.0, this EIC BAS programme aims at supporting EIC beneficiaries in their commercialisation strategy in European and foreign markets; it opens business avenues through participation in renown trade fairs in the EU, the Middle East and the United States of America (USA), as well as soft-landing activities in the USA, putting EU innovation under spotlight in some of the most promising markets of the world.



The EIC ITF 3.0 will attend trade fairs in 3 different regions:



United States



Europe



Middle East

The trade fairs will cover the following sectors:



New Technologies /
Industrial Technology



Health &
Medical Care



Biotech & Pharma



Cleantech /
Environment & Energy



3 ■

Meet the EIC awardees in attendance at BIO 2024



Ability Pharma



Acousort



Beats Medical



Genomtec



Iris AI



Kvantify



Mcule



MTM



Peptomyc



React4Life



SDS Optic



Stab Vida



Vaultree



Verigraft




Vitalera



4 ■ Find the EIC awardees at the European Pavilion

San Diego Convention Centre
Hall: B | Booth No: 1511





ABILITYPHARMA

Booth EX 1511 Ability Pharma European
Pavilion | Spain | Established in 2009
www.abilitypharma.com



Carles Domènech
Co-Founder & CEO
Carles.domenech@abilitypharma.com

Leading the way with autophagy to treat cancer selectively

AbilityPharma is a biopharma company developing first-in-class compounds in unmet oncological needs focused on autophagy as a new therapeutic approach to selectively kill cancer cells. Phase 2b trial in pancreatic cancer. All 140 patients recruited. Results available in 4Q2024.

Company's main achievements/credentials

- 2016: AbilityPharma signed a territorial license agreement for ABTL0812 with the US company SciClone Pharmaceuticals to develop and market the product in Greater China, with upfront and milestone payments over \$ 20 M

Solution(s) featuring at BIO 2024

AbilityPharma is developing innovative oral autophagy-inducing anticancer compounds. ABTL0812 causes the selective death of tumor cells through autophagy without affecting healthy cells. AbilityPharma is completing an international Phase 2b clinical trial with ABTL0812 in patients with metastatic pancreatic cancer, with the aim of demonstrating greater efficacy than the current standard treatment FOLFIRINOX. It is a double-blind, placebo-controlled, first-line study in combination with FOLFIRINOX chemotherapy, ongoing in 23 hospitals in Spain, the US, France, and Israel. All 140 patients included in the study have already been recruited. Efficacy results are expected in September 2024.

Target Business Partners

- Potential investors





ACOUSORT AB

Booth EX 1511 Acousort European
Pavilion | Sweden | Established in 2010
www.acousort.com



Torsten Freltoft
CEO
torsten.freltoft@acousort.com



Agnes Michanek
Sales / Marketing / CMO
agnes.michanek@acousort.com

Rapid biological sample preparation using acoustofluidics

AcouSort provides ultrasonic manipulation of biological fluids using microfluidic systems – providing high quality automated separation, washing and isolation of components in blood and various cell suspensions.

Company's main achievements/credentials

- AcouSort is ISO-13485 certified
- AcouSort's automated sample preparation technology is implemented in one of our partner's clinical diagnostic instruments and approved by US FDA for clinical use
- AcouSort's AcouWash technology was awarded among the world's 2018 top ten innovations by The Scientist

Solution(s) featuring at BIO 2024

The inPROBE technology is developed as a Technology platform, with laboratory prototypes already available for infectious disease diagnostics and drug delivery monitoring. These features position our technology as the future of diagnosis and health monitoring, uniquely integrating photonics with molecular biology, chemistry, and biomedical engineering. We have garnered preliminary interest from global pharmaceutical and medical technology companies, established a strong Scientific Advisory Board, and formed a Key Opinion Leaders society. Clinical trials in Poland have progressed, with Phase I concluded in 2023. We are actively expanding our international network for future development, cross-border trade, and scaling up inPROBE.

Target Business Partners

- Customers





BEATS MEDICAL

Booth EX 1511 Beats Medical European
Pavilion | Ireland | Established in 2018
<https://www.beatsmedical.com/>



Andrew Phelan
COO
andrew@beatsmedical.com



Ciara Clancy
CEO
ciara@beats-medical.com

Unlock the breakthrough CNS therapies of the future

Beats Medical are the world's leading digital assessment, therapy and biomarker specialists. Our patented platform technology, Colbolt, provides frictionless delivery of objective, repeatable assessments with enhanced sensitivity, without the need for additional hardware.

Company's main achievements/credentials

- Beats Medical's Colbolt platform technology is a Class 1 Medical device, with a proven quality track record, independently certified for ISO13485 compliance
- Deployments of Beats Medical's Colbolt platform have attained multiple awards, public and private health reimbursement, patient advocacy and charity endorsements
- Our unique precision digital assessment capabilities have been deployed by top-10 pharma to transform their approach to understanding and supporting complex CNS Conditions and Rare Diseases

Solution(s) featuring at BIO 2024

Beats Medical Colbolt Platform Technology – Colbolt is Beats Medical's platform technology that utilizes data from smartphone sensors to deliver objective, repeatable digital assessments with an embedded digital biomarkers focus using the smartphone. Beats Medical's patented approach allows for frictionless data collection with enhanced sensitivity, with data insights harmonized across iOS and Android. Using Colbolt, pharma partners can engage patients in their R&D activities in a Bring-Your-Own-Device solution, with no additional hardware or sensors required. Our advanced data insights and embedded digital biomarkers help our partners to realize their ambitions of unlocking the breakthrough therapies of the future.

Target Business Partners

- Customers
- Pharmaceutical Industry
- Investors





Genomtec S.A.

Booth EX 1511 Genomtec European
Pavilion | Poland | Established in 2016
www.genomtec.com



Charudutt Shah
CMO
c.shah@genomtec.com



Miron Tokarski
CEO
m.tokarski@genomtec.com

Genomtec delivers diagnostic solutions for POCT use

Genomtec S.A. is European medical diagnostics company dedicated to the commercialization of point-of-care genetic testing platform through the use of microfluidics technology, proprietary optical systems and Streamlined Nucleic Acid Amplification Technology SNAAT.

Company's main achievements/credentials

- Genomtec is certified under ISO13485.
- RP5-Plex panel for Genomtec ID system has been approved in European Union for in-vitro diagnostics of community occurred respiratory diseases and is marked with CE-IVD
- We have been awarded Seal of Excellence for Genomtec ID

Solution(s) featuring at BIO 2024

We offer technology ready to be implemented in partner's distribution network to offer POCT genetic-based testing solutions in infectious diseases detection. With proven partners in manufacturing we can scale-up manufacturing capacity to fit market needs. Due to versatility of the SNAAT platform it can also be utilised beyond clinical microbiology e.g. for CDx, personalised medicine and clinical studies of new therapies guided by molecular testing.

Target Business Partners

- VCs
- Investors,
- Strategic partners for licensing
- M&A and clinical cooperation with other healthcare groups



IRIS.AI

IRIS AI

Booth EX 1511 Iris AI European Pavilion |
Norway | Established in 2015
www.iris.ai



Victor Botev
Co-Founder & CTO
Victor@iris.ai



Jan Luprich
Business Development Manager
jan@iris.ai

Iris.ai: Research smarter with fact-based AI

Iris.ai offers a versatile, private Gen AI system, grounded in facts, for the toughest scientific knowledge processing tasks — from distilling novel insights in extensive literature collections to systematically extracting & linking data from patents. Backed by 8 years of R&D.

Company's main achievements/credentials

- 2023 Frost & Sullivan Enabling Technology Leadership Award
- 2022 EIC Accelerator Award
- 2020 Top 10 in AI for IBM Watson Good XPRIZE
- 2017 Fast Company Most Innovative Companies

Solution(s) featuring at BIO 2024

The Researcher Workspace (RW) is a versatile AI research assistant, designed specifically for biotech researchers and life science experts, that leverages credible, fact-based insights to support scientific endeavors. Aimed at eliminating tedious tasks that hinder research progress, this platform transforms the processing of scientific knowledge.

Target Business Partners

- Customers
- Investors
- Distributors in South America & Asia





KVANTIFY

Booth EX 1511 Kvantify European
Pavilion | Denmark | Established in 2022
www.kvantify.com



Michael Carter
Head of Drug Discovery
mc@kvantify.com



Nils Anton Berglund
Head of Strategic Alliances
nab@kvantify.com

Next Generation Physics-Driven Drug Discovery Platform

Kvantify is a software company leveraging AI, physics-based simulations, quantum and high performance computing to develop a next generation drug discovery platform. Our platform integrates novel physics-based computational methods with established AI methods.

Company's main achievements/credentials


- Awarded EIC accelerator grant in 2023, for further development of our drug discovery platform
- Collaboration with King's College London to leverage Kvantify's technology to tackle neurological disorders announced in 2023
- Performed the world's first calculation of an enzymatic reaction on a quantum computer with partners Novonosis in 2024

Solution(s) featuring at BIO 2024

Kvantify is presenting "Kvantify koffee" - a computational tool that accurately ranks small molecules according to their unbinding kinetics or k_{off} rates. This is the first tool launched in our drug discovery platform and aims to complement and reduce costly and time-consuming laboratory experiments.

Target Business Partners

- Customers





MCULE

Booth EX 1511 Mcule European Pavilion
| Hungary | Established in 2011
www.mcule.com



Greg Prikler
Director of Business Development
gprikler@mcule.com



Bence Barna
Custom Solutions Engineer
bence.barna@mcule.com

Mcule: One-stop-shop of small molecules for drug discovery

Mcule operates chemical marketplaces for drug discovery complemented with services based around small-molecule compound sourcing. We deliver compounds from in-stock and make-on-demand sources as well as via custom synthesis.

Company's main achievements/credentials

- Mcule was recognised as one of the top 1000 fastest growing companies in Europe by Financial Times in 4 years in a row (2021 - 2024)
- Mcule received grants in the H2020 framework (no. 777828) and Horizon Europe framework (no. 101057564) and was awarded by the National Research, Development and Innovation office in Hungary

Solution(s) featuring at BIO 2024

The INFINITY technology was introduced to the market in late 2023, after the BIO US 2023. This search engine can cover a space of around ten trillion novel chemical compounds that could be synthesized on demand, based on the building blocks of our integrated supplier partners. This is a highly diverse and novel expansion of the currently available chemical space for the researchers, which Mcule will showcase at BIO 2024.

Target Business Partners

- Private Procurers
- Customers





MTM Srl

Booth EX 1511 MTM European Pavilion |
Italy | Established in 2012
www.mtmsrl.eu



Riccardo Roggeri
CSO
info@mtmsrl.eu



Clara Bernasco
Chief of Internationalization
clara.bernasco@gmail.com

ROG is the game-changing platform for surgical operations

MTM s.r.l. is a private research company based in Milan (Italy) specialising in the fields of Biotechnology, New Materials, IoT technologies & system integration in Bio-Tech and Biomedical sector.

Company's main achievements/credentials

- The company was selected in 2022 by the EIC as one of the most valuable in Europe within European SMEs

Solution(s) featuring at BIO 2024

The ROG project aims to develop new software and hardware components useful for offering a new three-dimensional (3D) printable digital modelling service, focussed on the human heart and its pathologies, as a support tool for the simulation of surgical interventions, medical-scientific training and doctor-patient communication in a field, that of cardiovascular diseases, among the most important for public health.

Target Business Partners

- Investors
- Public procurers
- Hospitals and Research Centers



PEPTOMYC

Booth EX 1511 Peptomyc European
Pavilion | Spain | Established in 2014
www.peptomyc.com



Marie-Eve Beaulieu
Co-Founder & Chief Scientific
Officer
Mbeaulieu@peptomyc.com



Joerg Klumbis
CFO
Jklumbis@peptomyc.com

We revolutionize cancer treatment with anti-MYC mini-proteins

MYC is a most-wanted cancer target found deregulated in ~70% of all cancers. Peptomyc is the first company to have successfully completed a First-in-Humans clinical trial with OMO-103, the first direct pan-MYC inhibitor showing excellent safety and clinical activity in cancer patients (Nat Med, Feb 2024).

Company's main achievements/credentials

- 2023: Phase 1b clinical trial started in 18 metastatic pancreatic cancer patients, combining OMO-103 with standard of care chemotherapy (Gemcitabine + Nab-paclitaxel). Our predictive biomarkers are being used to select patients more likely to respond to therapy. Peptomyc is awarded EIC accelerator funding of 5M€
- 2024: OMO-103 is being developed as a "pipeline in an asset", for direct brain delivery for glioblastoma treatment, and as tumor-targeted agent, among others. Total fundraised to date 42M€ (private 31M€, public grants & loans 11M€)

Solution(s) featuring at BIO 2024

OMO-103 is a patented, intravenously-delivered first-in-class cell-penetrating mini-protein based on Omomyc, the best MYC inhibitor to date that has shown therapeutic impact, negligible side effects, and no resistance even after prolonged treatment in preclinical models of various cancer types.

Target Business Partners

- Potential investors





REACT4LIFE

Booth EX 1511 React4Life European
Pavilion | Italy | Established in 2016
www.react4life.com



Silvia Scaglione
Research & Development / CRO
s.scaglione@react4life.com



Maurizio Aiello
CEO
m.aiello@react4life.com

Advance Disease Understanding & Drug Test via Organ-on-Chip

React4Life is an Italian SME producing organ-on-chip device, like MIVO®, to overcome the constraints of traditional in vitro assays and animal models. MIVO revolutionizes the preclinical research landscape, enhancing the reliability and predictivity in diverse applications.

Company's main achievements/credentials

- Best Health Technology award by Innovation Radar (European Commission in 2021 and Accelerating Innovation award (CPII) in 2023)
- React4life has successfully completed important validations in oncology and immuno-oncology, where the MIVO based technologies enable to resemble in vitro immune cells infiltration into 3D patient derived tumors, providing fully humanized, reproducible and cruelty free models for testing immuno- and cell-therapies

Solution(s) featuring at BIO 2024

- MIVO-based cancer on chip
- MIVO -Multi in vitro Organs platforms

Target Business Partners

- Distributors
- Customers





SDS OPTIC

Booth EX 1511 SDS Optic European
Pavilion | Poland | Established in
2013
www.sdsoptic.pl



Karol Maryniowski
Sales / Marketing / CMO
kmaryniowski@sdsoptic.pl



Mateusz Sagan
CEO
msagan@sdsoptic.pl

Lifesaving innovations

SDS Optic connects molecular biology, photonics, chemistry & biomedical engineering in a single platform technology focusing on cancer biomarkers diagnostics.

Company's main achievements/credentials

- Confirmed QMS with ISO13485 Certification for Medical Devices
- Innovation Radar Prize 2020: "Women-led Innovation" award
- The Polish Product of the Future award
- Several recognitions as The Company/Debut of the Year from NewConnect Stock Exchange Market
- Several distinctions as one of the most innovative Companies in Europe (The European Commission, EIC)

Solution(s) featuring at BIO 2024

inPROBE® is first ever In Vivo Photonics Immunoassays platform with a prime focus on HER2 diagnostics in breast cancers.

Target Business Partners

- Investors
- Distributors
- Key Opinion Leaders (physicians/scientists)
- R&D companies
- Potential partners
- Potential buyers of the technology
- Accelerators





STABVIDA

Booth EX 1511 Stabvida European
Pavilion | Portugal | Established in 2001
www.stabvida.com



Orfeu Flores
CEO
orfeu.flores@stabvida.com



Eduardo Coelho
Research & Development / CRO
eduardo.coelho@stabvida.com

DoctorVida Onsite Legionella molecular test in water samples

Doctor Vida, the market-ready portable PCR device developed and manufactured by STAB VIDA, allows POC testing for Legionella pneumophila in water samples. The simple workflow and portable equipment allows on-site decision to be made in approximately 1 h, instead of 8-14 days.

Company's main achievements/credentials

- STAB VIDA is a pioneering Portuguese biotech firm ISO 9001 certified since 2010. STAB VIDA won 2 Seals of Excellence from the European Innovation Council.
- 2015 till 2022 - SME Leadership Prize from IAPMEI
- 2021 - Doctor Vida Pocket PCR holds CE-IVD certification and is ISO 13485 compliant
- 2021 - 2023 - Innovator Company, ISO 13485 compliant

Solution(s) featuring at BIO 2024

Doctor Vida Pocket PCR - Legionella pneumophila Test

Target Business Partners

- Distributors
- Public Procurers
- Private Procurers
- Customers (Healthcare Facilities/Commercial Buildings/Public Facilities and Local Governments etc.)





VAULTREE

Booth EX 1511 Vaultree European
Pavilion | Ireland | Established in 2020
www.vaultree.com



Ryan Lasmaili
Co-founder and CEO
ryan@vaultree.com



Alessandro Watson
Head of Solutions
Alessandro.watson@vaultree.com

Real-time encrypted data processing at scale to solve the biopharma industry's fundamental security issue

Vaultree's Data-In-Use Encryption is a groundbreaking innovation in the space. Unlike traditional or other advanced encryption methods, Vaultree ensures data remains encrypted even during highly complex processes and computations, and that at plaintext speed!

Company's main achievements/credentials


- Data in use encryption breakthrough
- Received A round funding December 2023

Solution(s) featuring at BIO 2024

- Data-In-Use Encryption SDK
- VEDS - Vaultree Encrypted Data Sharing
- Vaultree Vault

Target Business Partners

- Distributors
- Customers





VERIGRAFT

Booth EX 1511 Verigrift European
Pavilion | Sweden | Established in 2014
www.verigrift.com



Pernilla Gill
Head Market Relations
Pernilla.gill@verigrift.com

Personalized Transplants Enabling Regenerative Medicine

VERIGRAFT is a pioneer in regenerative medicine since 2014 and has grown to become a forerunner in industrialized tissue therapies and advanced regenerative medicine. The company has a strategically focused R&D pipeline of personalized tissues, targeting areas such as cardiovascular and neuronal disease for a global market.

Company's main achievements/credentials

- Our P-TEV grafts for the treatment of chronic venous insufficiency are in clinical trials in Europe (supported by SMEInstrument grant)
- Our personalized artery grafts are in late preclinical development, planned to enter clinical development towards the end of the year (supported by Eurostars grant)
- Our personalized vascular networks are under development and prototyping as part of the EC funded 4DBR project

Solution(s) featuring at BIO 2024

VERIGRAFT develops and commercializes advanced therapies. The company produces natural, fully personalized grafts for the treatment of chronic and severe diseases. The advanced therapies presented at Bio2024:

- Personalized tissue-engineered vein (P-TEV) grafts in clinical trials proving safety and efficacy. VERIGRAFT P-TEVTM is used to treat the cause of severe chronic venous insufficiency (CVI).
- Personalized tissue-engineered artery (P-TEA) grafts are in late preclinical development. VERIGRAFT P-TEATM enables peripheral and cardiac arterial regeneration or bypass.

Target Business Partners

- Potential investors



VITALERA

Booth EX 1511 Vitalera European
Pavilion | Spain | Established in 2018
www.vitalera.io



Nuria Pastor
Co-Founder & CEO
nuria.pastor@humanitcare.com

We use AI to radically improve people's access to healthcare

Revolutionary remote care AI solution, compatible with diverse medical devices. Enables real-time data analysis, remote monitoring, and seamless integration with EHR/EMR. Partnered with BIMC (Harvard Medical School) & other major players.

Company's main achievements/credentials

- 2018 - working with top-tier pharmaceutical companies, among other clients
- 2019 - all the regulatory processes and data security and privacy
- 2021 - EIC awarded 2.5M€
- 2023 - scaling business to US

Solution(s) featuring at BIO 2024

In this line, HumanITcare offers a patient-centered solution, an analysis of the clinical processes through all the data gathered, and the potential to develop AI-based solutions. There are many types of customers interested in this kind of solution: healthcare providers (such as clinics and hospitals), insurers, pharmaceutical corporations (especially for the management of clinical studies), and digital health providers (interested in our API).

Target Business Partners

- Healthcare providers (hospitals and clinics)
- Pharmaceutical Companies
- Insurances and digital health providers






European
Innovation
Council



EIC International
Trade Fairs
Programme 3.0



eic.ec.europa.eu